Evidence map›Paper›PMID 39198434›Full record

ArticleCell death & disease2024

Intelligent drugs based on notch protein remodeling: a defensive targeting strategy for tumor therapy.

Yuliang Sun, Yilin Lu, Xinze Li, Yanan He, Then Kong Yong, Cheong Soon Keng, Badrul Yahaya, Yanli Liu, Juntang Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuliang Sun *Stem Cell and Biotherapy Technology Research Center, Xinxiang Medical University, Xinxiang, 453003, China.
Yilin Lu *Stem Cell and Biotherapy Technology Research Center, Xinxiang Medical University, Xinxiang, 453003, China.
Xinze LiStem Cell and Biotherapy Technology Research Center, Xinxiang Medical University, Xinxiang, 453003, China.
Yanan HeStem Cell and Biotherapy Technology Research Center, Xinxiang Medical University, Xinxiang, 453003, China.
Then Kong YongCryoCord Sdn Bhd, Bio-X Centre, 63000, Cyberjaya, Selangor, Malaysia.
Cheong Soon KengCryoCord Sdn Bhd, Bio-X Centre, 63000, Cyberjaya, Selangor, Malaysia.
Badrul YahayaDepartment of Biomedical Sciences, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia, SAINS@BERTAM, 13200, Kepala Batas, Penang, Malaysia. badrul@usm.my.
Yanli LiuStem Cell and Biotherapy Technology Research Center, Xinxiang Medical University, Xinxiang, 453003, China. liuyanli198512@163.com.
Juntang LinStem Cell and Biotherapy Technology Research Center, Xinxiang Medical University, Xinxiang, 453003, China. linjtlin@126.com.ORCID 0000-0001-9300-1771

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the process of tumor treatment, systemic drug administration is hindered by biological barriers, leading to the retention of a large number of drug molecules in healthy tissues and causing unavoidable side effects. The precise deployment of drugs at the tumor site is expected to alleviate this phenomenon. Here, we take endostatin and Her2 (+) tumors as examples and develop an intelligent drug with simple "wisdom" by endowing mesenchymal stem cells (MSCs) with an intelligent response program (iMSC

Indexed as

Receptors, NotchAnimalsAntineoplastic AgentsCell Line, TumorHumansMesenchymal Stem CellsMiceNeoplasmsAntineoplastic AgentsReceptors, Notch

Identifiers

PMID39198434
PMCPMC11358381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.